Liposome delivery systems for the treatment of Alzheimer’s disease

References

• World Health OrganizationNeurological Disorders: Public Health ChallengesGenevaWHO2006
   Google Scholar
• PrinceMAliG-CGuerchetMPrinaAMAlbaneseEWuY-TRecent global trends in the prevalence and incidence of dementia, and survival with dementiaAlzheimers Res Ther2016811327005937
   PubMedGoogle Scholar
• KrsticDKnueselIDeciphering the mechanism underlying late-onset Alzheimer diseaseNat Rev Neurol201391253423183882
   PubMed Web of Science ®Google Scholar
• KarranEde StrooperBThe amyloid cascade hypothesis: are we poised for success or failure?J Neurochem2016139Suppl 223725227255958
   PubMedGoogle Scholar
• MurphyMPLevineHAlzheimer’s disease and the amyloid-β peptideJ Alzheimers Dis201019131132320061647
   PubMed Web of Science ®Google Scholar
• HaassCSelkoeDJSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptideNat Rev Mol Cell Biol20078210111217245412
   PubMed Web of Science ®Google Scholar
• LiptonSAGuZNakamuraTInflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disordersInt Rev Neurobiol20078212717678953
   PubMed Web of Science ®Google Scholar
• MoreiraPISiedlakSLAlievGOxidative stress mechanisms and potential therapeutics in Alzheimer diseaseJ Neural Transm2005112792193215583960
   PubMed Web of Science ®Google Scholar
• OddoSLaferlaFMThe role of nicotinic acetylcholine receptors in Alzheimer’s diseaseJ Physiol Paris2006992–317217916448808
   PubMedGoogle Scholar
• HansenRAGartlehnerGWebbAPMorganLCMooreCGJonasDEEfficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysisClin Interv Aging20083221122518686744
   PubMed Web of Science ®Google Scholar
• YiannopoulouKGPapageorgiouSGCurrent and future treatments for Alzheimer’s diseaseTher Adv Neurol Disord201361193323277790
   PubMed Web of Science ®Google Scholar
• BrownDSuperti-FurgaGRediscovering the sweet spot in drug discoveryDrug Discov Today20038231067107714693466
   PubMed Web of Science ®Google Scholar
• SzuromiPVinsonVMarshallERethinking drug discovery – IntroductionScience200430356651795
   Web of Science ®Google Scholar
• OveringtonJPAl-LazikaniBHopkinsALHow many drug targets are there?Nat Rev Drug Discov200651299399617139284
   PubMed Web of Science ®Google Scholar
• GregoriMMasseriniMManciniSNanomedicine for the treatment of Alzheimer’s diseaseNanomedicine20151071203121825929574
   PubMed Web of Science ®Google Scholar
• WolburgHNoellSMackAWolburg-BuchholzKFallier-BeckerPBrain endothelial cells and the glio-vascular complexCell Tissue Res20093351759618633647
   PubMed Web of Science ®Google Scholar
• LaiFFaddaAMSinicoCLiposomes for brain deliveryExpert Opin Drug Deliv20131071003102223373728
   PubMed Web of Science ®Google Scholar
• VieiraDBGamarraLFGetting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrierInt J Nanomedicine2016115381541427799765
   PubMed Web of Science ®Google Scholar
• NobleGTStefanickJFAshleyJDKiziltepeTBilgicerBLigand-targeted liposome design: challenges and fundamental considerationsTrends Biotechnol2014321324524210498
   PubMed Web of Science ®Google Scholar
• BhowmikAKhanRGhoshMKBlood brain barrier: a challenge for effectual therapy of brain tumorsBiomed Res Int20152015120
   Web of Science ®Google Scholar
• Sánchez-NavarroMGiraltETeixidóMBlood-brain barrier peptide shuttlesCurr Opin Chem Biol20173813414028558293
   PubMed Web of Science ®Google Scholar
• AbbottNJPatabendigeAADolmanDEYusofSRBegleyDJStructure and function of the blood-brain barrierNeurobiol Dis2010371132519664713
   PubMed Web of Science ®Google Scholar
• ChenYLiuLModern methods for delivery of drugs across the blood-brain barrierAdv Drug Deliv Rev201264764066522154620
   PubMed Web of Science ®Google Scholar
• HershDSWadajkarASRobertsNEvolving drug delivery strategies to overcome the blood brain barrierCurr Pharm Des20162291177119326685681
   PubMed Web of Science ®Google Scholar
• AgrawalMAjazuddinTripathiDKRecent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer’s diseaseJ Control Release2017260617728549949
   PubMed Web of Science ®Google Scholar
• LiWZhouYZhaoNHaoBWangXKongPPharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomesEnviron Toxicol Pharmacol201234227227922613079
   PubMed Web of Science ®Google Scholar
• ZhengXShaoXZhangCIntranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer’s diseasePharm Res201532123837384926113236
   PubMed Web of Science ®Google Scholar
• IllumLNasal drug delivery – recent developments and future prospectsJ Control Release2012161225426322300620
   PubMed Web of Science ®Google Scholar
• GaoHProgress and perspectives on targeting nanoparticles for brain drug deliveryActa Pharm Sin B20166426828627471668
   PubMed Web of Science ®Google Scholar
• PatchingSGGlucose transporters at the blood-brain barrier: Function, regulation and gateways for drug deliveryMol Neurobiol20175421046107726801191
   PubMed Web of Science ®Google Scholar
• ArumugamKSubramanianGSMallayasamySRAverineniRKReddyMSUdupaNA study of rivastigmine liposomes for delivery into the brain through intranasal routeActa Pharm200858328729719103565
   PubMed Web of Science ®Google Scholar
• MutluNBDeğimZYilmazŞEşsizDNacarANew perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulationsDrug Dev Ind Pharm201137777578921231901
   PubMed Web of Science ®Google Scholar
• ConfaloniATostoGTataAMPromising therapies for Alzheimer’s diseaseCurr Pharm Des201622142050205626876218
   PubMed Web of Science ®Google Scholar
• SpuchCNavarroCLiposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease)J Drug Deliv2011469679
   Google Scholar
• JoshiSSingh-MoonRPEllisJACerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing ratsNeurosurgery20157619210025525695
   PubMed Web of Science ®Google Scholar
• AbraRMHuntCALiposome disposition in vivo. III. Dose and vesicle-size effectsBiochim Biophys Acta198166634935037034780
   PubMedGoogle Scholar
• HarashimaHKiwadaHLiposomal targeting and drug delivery: kinetic considerationAdv Drug Deliv Rev1996193425444
   Web of Science ®Google Scholar
• FanciullinoRCiccoliniJLiposome-encapsulated anticancer drugs: still waiting for the magic bullet?Curr Med Chem200916334361437319835568
   PubMed Web of Science ®Google Scholar
• AllenTMLiposomes. Opportunities in drug deliveryDrugs199754Suppl 4814
   PubMed Web of Science ®Google Scholar
• BriugliaMLRotellaCMcFarlaneALamprouDAInfluence of cholesterol on liposome stability and on in vitro drug releaseDrug Deliv Transl Res20155323124225787731
   PubMed Web of Science ®Google Scholar
• AlarcónJMBritoJAHermosillaTAtwaterIMearsDRojasEIon channel formation by Alzheimer’s disease amyloid β-peptide (Aβ40) in unilamellar liposomes is determined by anionic phospholipidsPeptides20062719510416139931
   PubMed Web of Science ®Google Scholar
• KuoYCLinCYLiJSLouYIWheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer’s disease treatmentInt J Nanomedicine2017121757177428280340
   PubMed Web of Science ®Google Scholar
• PalchettiSColapicchioniVDigiacomoLThe protein corona of circulating PEGylated liposomesBiochim Biophys Acta20161858218919626607013
   PubMed Web of Science ®Google Scholar
• VeroneseFMMeroAThe impact of PEGylation on biological therapiesBioDrugs200822531532918778113
   PubMed Web of Science ®Google Scholar
• BallatoriNKranceSMMarchanRHammondCLPlasma membrane glutathione transporters and their roles in cell physiology and pathophysiologyMol Aspects Med2009301–2132818786560
   PubMed Web of Science ®Google Scholar
• GaillardPJAppeldoornCCDorlandRPharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)PLoS One20149110
   Web of Science ®Google Scholar
• RotmanMWellingMMBunschotenAEnhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer’s diseaseJ Control Release2015203405025668771
   PubMed Web of Science ®Google Scholar
• ZhangCXZhaoWYLiuLA nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatmentOncotarget2015632326813270026418720
   PubMed Web of Science ®Google Scholar
• XieFYaoNQinYInvestigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targetingInt J Nanomedicine2012716317522275832
   PubMed Web of Science ®Google Scholar
• LiHQianZMTransferrin/transferrin receptor-mediated drug deliveryMed Res Rev200222322525011933019
   PubMed Web of Science ®Google Scholar
• FishmanJBRubinJBHandrahanJVConnorJRFineREReceptor-mediated transcytosis of transferrin across the blood-brain barrierJ Neurosci Res19871822993043694713
   PubMed Web of Science ®Google Scholar
• GaoJQLvQLiLMGlioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomesBiomaterials201334225628563923628475
   PubMed Web of Science ®Google Scholar
• ChenZLHuangMWangXRTransferrin-modified liposome promotes α-mangostin to penetrate the blood-brain barrierNanomedicine201612242143026711963
   PubMed Web of Science ®Google Scholar
• ChenYCChiangCFChenLFLiangPCHsiehWYLinWLPolymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery systemBiomaterials201435134066408124513319
   PubMed Web of Science ®Google Scholar
• PapadiaKMarkoutsaEMourtasSMultifunctional LUV liposomes decorated for BBB and amyloid targeting. A. In vitro proof-of-conceptEur J Pharm Sci201710114014828193538
   PubMed Web of Science ®Google Scholar
• SongXLLiuSJiangYTargeting vincristine plus tetrandrine liposomes modified with DSPE-PEG2000-transferrin in treatment of brain gliomaEur J Pharm Sci20179612914027644895
   PubMed Web of Science ®Google Scholar
• ChenHTangLQinYLactoferrin-modified procationic liposomes as a novel drug carrier for brain deliveryEur J Pharm Sci20104029410220298779
   PubMed Web of Science ®Google Scholar
• KawamataTTooyamaIYamadaTWalkerDGMcGeerPLLactotransferrin immunocytochemistry in Alzheimer and normal human brainAm J Pathol19931425157415858494052
   PubMed Web of Science ®Google Scholar
• ZhongZ-RLiuJDengYPreparation and characterization of a novel nonviral gene transfer system: procationic-liposome-protamine-DNA complexesDrug Deliv200714317718317454038
   PubMed Web of Science ®Google Scholar
• MahleyRWApolipoprotein E: cholesterol transport protein with expanding role in cell biologyScience198824048526226303283935
   PubMed Web of Science ®Google Scholar
• GobbiMReFCanoviMLipid-based nanoparticles with high binding affinity for amyloid-β1-42 peptideBiomaterials201031256519652920553982
   PubMed Web of Science ®Google Scholar
• ReFCambianicaISesanaSFunctionalization with ApoE- derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-β peptideJ Biotechnol2011156434134621763360
   PubMed Web of Science ®Google Scholar
• Lane-DonovanCWongWMDurakoglugilMSGenetic restoration of plasma ApoE improves cognition and partially restores synaptic defects in ApoE-deficient miceJ Neurosci20163639101411015027683909
   PubMed Web of Science ®Google Scholar
• LindgrenMHällbrinkMProchiantzALangelUCell-penetrating peptidesTrends Pharmacol Sci20002139910310689363
   PubMed Web of Science ®Google Scholar
• GregoriMTaylorMSalvatiERetro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer’s Aβ peptideNanomedicine201713272373227769888
   PubMed Web of Science ®Google Scholar
• VivèsERichardJPRispalCLebleuBTAT peptide internalization: seeking the mechanism of entryCurr Protein Pept Sci20034212513212678851
   PubMed Web of Science ®Google Scholar
• ParthsarathyVMcCleanPLHölscherCA novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer’s diseasePLoS One20138911
   Google Scholar
• KameiNTanakaMChoiHEffect of an enhanced nose-to-brain delivery of insulin on mild and progressive memory loss in the senescence-accelerated mouseMol Pharm201714391692728094952
   PubMedGoogle Scholar
• HardyJAllsopDAmyloid deposition as the central event in the aetiology of Alzheimer’s diseaseTrends Pharmacol Sci199112103833881763432
   PubMed Web of Science ®Google Scholar
• HardyJSelkoeDJThe amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeuticsScience2002297558035335612130773
   PubMed Web of Science ®Google Scholar
• BalducciCManciniSMinnitiSMultifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer’s disease mouse modelsJ Neurosci20143442140221403125319699
   PubMed Web of Science ®Google Scholar
• BanaLMinnitiSSalvatiELiposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer diseaseNanomedicine20141071583159024333591
   PubMed Web of Science ®Google Scholar
• MatsuokaYSaitoMLafrancoisJNovel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to β-amyloidJ Neurosci2003231293312514198
   PubMed Web of Science ®Google Scholar
• ManciniSMinnitiSGregoriMThe hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer diseaseNanomedicine20161214352
   PubMed Web of Science ®Google Scholar
• FriedlichALButcherLLInvolvement of free oxygen radicals in β- amyloidosis: an hypothesisNeurobiol Aging19941544434557969721
   PubMed Web of Science ®Google Scholar
• TabnerBJEl-AgnafOMTurnbullSHydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementiaJ Biol Chem200528043357893579216141213
   PubMed Web of Science ®Google Scholar
• BehlCDavisJBLesleyRSchubertDHydrogen peroxide mediates amyloid β protein toxicityCell19947768178278004671
   PubMed Web of Science ®Google Scholar
• SanoMErnestoCThomasRGA controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer’s diseaseN Engl J Med Overseas Ed19973361712161222
   PubMed Web of Science ®Google Scholar
• LimGPChuTYangFBeechWFrautschySAColeGMThe curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouseJ Neurosci200121218370837711606625
   PubMed Web of Science ®Google Scholar
• YanagisawaDAmatsuboTMorikawaSIn vivo detection of amyloid β deposition using 19F magnetic resonance imaging with a 19F-containing curcumin derivative in a mouse model of Alzheimer’s diseaseNeuroscience201118412012721497641
   PubMed Web of Science ®Google Scholar
• LeeIYangJLeeJHChoeYSSynthesis and evaluation of 1-(4-[18F]fluoroethyl)-7-(4′-methyl)curcumin with improved brain permeability for β-amyloid plaque imagingBioorg Med Chem Lett201121195765576921885280
   PubMed Web of Science ®Google Scholar
• YanagisawaDIbrahimNFTaguchiHCurcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 miceNeurobiol Aging201536120121025179227
   PubMed Web of Science ®Google Scholar
• TaylorMMooreSMourtasSEffect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer’s Aβ peptideNanomedicine20117554155021722618
   PubMed Web of Science ®Google Scholar
• MourtasSLazarANMarkoutsaEDuyckaertsCAntimisiarisSGMultifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer diseaseEur J Med Chem20148017518324780594
   PubMed Web of Science ®Google Scholar
• AustenBMPaleologouKEAliSAQureshiMMAllsopDEl-AgnafOMDesigning peptide inhibitors for oligomerization and toxicity of Alzheimer’s β-amyloid peptideBiochemistry20084771984199218189413
   PubMed Web of Science ®Google Scholar
• TaylorMMooreSMayesJDevelopment of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer’s diseaseBiochemistry201049153261327220230062
   PubMed Web of Science ®Google Scholar
• ShererMFullwoodNJTaylorMAllsopDA preliminary electron microscopic investigation into the interaction between Aβ1-42 peptide and a novel nanoliposome-coupled retro-inverso peptide inhibitor, developed as a potential treatment for Alzheimer’s diseaseJ Phys Conference Series2015644012040
   Google Scholar
• EisenbergDJuckerMThe amyloid state of proteins in human diseasesCell201214861188120322424229
   PubMed Web of Science ®Google Scholar
• TenovuoOCentral acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patientsProg Neuropsychopharmacol Biol Psychiatry2005291616715610946
   PubMed Web of Science ®Google Scholar
• SpencerCMNobleSRivastigmine. A review of its use in Alzheimer’s diseaseDrugs Aging19981353914119829166
   PubMed Web of Science ®Google Scholar
• IllumLNasal drug delivery – possibilities, problems and solutionsJ Control Release2003871–318719812618035
   PubMed Web of Science ®Google Scholar
• YangZZZhangYQWangZZWuKLouJNQiXREnhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administrationInt J Pharm20134521–234435423680731
   PubMed Web of Science ®Google Scholar
• YadavAVMurthyMSSheteASSakhareSStability aspects of liposomesIndian J Pharm Educ Res2011454402413
   Web of Science ®Google Scholar
• Nageeb El-HelalySAbd ElbaryAKassemMAEl-NabarawiMAElectrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studiesDrug Deliv201724169270028415883
   PubMed Web of Science ®Google Scholar
• KreuterJAlyautdinRNKharkevichDAIvanovAAPassage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)Brain Res199567411711747773690
   PubMed Web of Science ®Google Scholar
• MandellJWBankerGAA spatial gradient of tau protein phosphorylation in nascent axonsJ Neurosci19961618572757408795628
   PubMed Web of Science ®Google Scholar
• LuoQLinY-XYangP-PA self-destructive nanosweeper that captures and clears amyloid β-peptidesNat Commun2018911229295991
   PubMedGoogle Scholar
• GotoYDuthieMSKawazuSInoueNCarterDBiased cellular locations of tandem repeat antigens in African trypanosomesBiochem Biophys Res Commun2011405343443821241659
   PubMed Web of Science ®Google Scholar
• JunS-RWassenaarTMWanchaiVPatumcharoenpolPNookaewIUsseryDWSuggested mechanisms for Zika virus causing microcephaly: what do the genomes tell us?BMC Bioinformatics201718S141228049428
   PubMedGoogle Scholar
• van EttenEWTen KateMTSnijdersSVBakker-WoudenbergIAAdministration of liposomal agents and blood clearance capacity of the mononuclear phagocyte systemAntimicrob Agents Chemother1998427167716819661003
   PubMed Web of Science ®Google Scholar
• TohM-RChiuGNCLiposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturingAsian J Pharm Sci2013828895
   Google Scholar
• PaytonNMWempeMFXuYAnchordoquyTJLong-term storage of lyophilized liposomal formulationsJ Pharm Sci2014103123869387825308534
   PubMed Web of Science ®Google Scholar
• ChenCHanDCaiCTangXAn overview of liposome lyophilization and its future potentialJ Control Release2010142329931119874861
   PubMed Web of Science ®Google Scholar
• QianZMLiHSunHHoKTargeted drug delivery via the transferrin receptor-mediated endocytosis pathwayPharmacol Rev200254456158712429868
   PubMed Web of Science ®Google Scholar
• GuoLRenJJiangXPerspectives on brain-targeting drug delivery systemsCurr Pharm Biotechnol201213122310231823016637
   PubMed Web of Science ®Google Scholar
• FillebeenCDescampsLDehouckMPReceptor-mediated transcytosis of lactoferrin through the blood-brain barrierJ Biol Chem1999274117011701710066755
   PubMed Web of Science ®Google Scholar
• DerossiDJoliotAHChassaingGProchiantzAThe third helix of the Antennapedia homeodomain translocates through biological membranesJ Biol Chem19942691410444104508144628
   PubMed Web of Science ®Google Scholar
• FutakiSOhashiWSuzukiTStearylated arginine-rich peptides: a new class of transfection systemsBioconjug Chem20011261005101111716693
   PubMed Web of Science ®Google Scholar
• LuWZhangYTanYZHuKLJiangXGFuSKCationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain deliveryJ Control Release2005107342844816176844
   PubMed Web of Science ®Google Scholar
• TsengYLLiuJJHongRLTranslocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy studyMol Pharmacol200262486487212237333
   PubMed Web of Science ®Google Scholar
• HenriquesSTCastanhoMATranslocation or membrane disintegration? Implication of peptide-membrane interactions in pep-1 activityJ Pept Sci200814448248718181239
   PubMed Web of Science ®Google Scholar
• GaoCMaoSDitzelHJA cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide libraryBioorg Med Chem200210124057406512413859
   PubMed Web of Science ®Google Scholar
• KorenETorchilinVPCell-penetrating peptides: breaking through to the other sideTrends Mol Med201218738539322682515
   PubMed Web of Science ®Google Scholar
• PoogaMHällbrinkMZorkoMLangelUCell penetration by transportanFASEB J199812167779438412
   PubMed Web of Science ®Google Scholar
• WenderPAMitchellDJPattabiramanKPelkeyETSteinmanLRothbardJBThe design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transportersProc Natl Acad Sci U S A20009724130031300811087855
   PubMed Web of Science ®Google Scholar
• de CoupadeCFittipaldiAChagnasVNovel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomoleculesBiochem J2005390Pt 240741815859953
   PubMed Web of Science ®Google Scholar
• MorrisMCDeshayesSHeitzFDivitaGCell-penetrating peptides: from molecular mechanisms to therapeuticsBiol Cell2008100420121718341479
   PubMed Web of Science ®Google Scholar
• JohanssonHJEl-AndaloussiSHolmTCharacterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF proteinMolecular Therapy2008161115123
   Web of Science ®Google Scholar
• TaylorBNMehtaRRYamadaTNoncationic peptides obtained from azurin preferentially enter cancer cellsCancer Res200969253754619147567
   PubMed Web of Science ®Google Scholar
• MagzoubMSandgrenSLundbergPN-terminal peptides from unprocessed prion proteins enter cells by macropinocytosisBiochem Biophys Res Commun2006348237938516893522
   PubMed Web of Science ®Google Scholar
• OehlkeJKrauseEWiesnerBBeyermannMBienertMExtensive cellular uptake into endothelial cells of an amphipathic β-sheet forming peptideFEBS Lett199741521961999350995
   PubMed Web of Science ®Google Scholar
• SadlerKEomKDYangJLDimitrovaYTamJPTranslocating proline-rich peptides from the antimicrobial peptide bactenecin 7Biochemistry20024148141501415712450378
   PubMed Web of Science ®Google Scholar
• RheeMDavisPMechanism of uptake of C105Y, a novel cell-penetrating peptideJ Biol Chem200628121233124016272160
   PubMed Web of Science ®Google Scholar